REG - Hikma Pharmaceutical - Director/PDMR Shareholding <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

19/05/2016 10:20

RNS Number : 7266Y
Hikma Pharmaceuticals Plc
19 May 2016
Hikma Pharmaceuticals PLC - Vesting of 2013 LTIP
LONDON, 19 May 2016: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") announces that the following Directors and Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 17 May 2016 under the 2005 Long Term Incentive Plan ("LTIP") which was completed on 19 May 2016. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is nil. As indicated in the table below, certain PDMRs have made disposals.
In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over Hikma's Ordinary Shares of 10p each ("Shares") as detailed below.
PDMR
Type of Transaction
Shares Acquired under LTIP
Date
Price
Shares Disposed
Remaining Holding
Said Darwazah
Vesting of LTIP 2013
88,383
(0.04% ISC)
19 May 2016
N/A
Nil
13,265,884*
(5.54% ISC)
Mazen Darwazah
Vesting of LTIP 2013
45,924
(0.02% ISC)
19 May 2016
N/A
Nil
7,256,131*
(3.03% ISC)
Bassam Kanaan
Vesting of LTIP 2013 & Disposal
34,660
(0.01% ISC)
19 May 2016
22.42
34,660
418,658
(0.19% ISC)
Michael Raya
Vesting of LTIP 2013 & Disposal
32,927
(0.01% ISC)
19 May 2016
22.42
19,047
133,840
(0.06% ISC)
Riad Mishlawi
Vesting of LTIP 2013
19,063
(0.01% ISC)
19 May 2016
N/A
Nil
119,090
(0.05% ISC)
Khalid Nabilsi
Vesting of LTIP 2013
19,063
(0.01% ISC)
19 May 2016
N/A
Nil
221,921
(0.09% ISC)
Majda Labadi
Vesting of LTIP 2013
14,848
(0.01% ISC)
19 May 2016
N/A
Nil
187,431
(0.08% ISC)
"ISC" = Issued Share Capital of Hikma which is 239,385,501 Shares following the release of the LTIP 2013.
* Said Darwazah has a direct interest in Hikma of 745,383 Shares and an effective interest in Hikma through his interest in Darhold Limited of 12,520,501 Shares. Mazen Darwazah has a direct interest in Hikma of 952,965 Shares and an effective interest in Hikma through his interest in Darhold Limited of 6,303,166 Shares.
- ENDS -
Enquiries 
Peter Speirs   +44 20 7399 2760
Company Secretary, Hikma Pharmaceuticals PLC
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHGCGDUSBBBGLC